madman
Super Moderator
SUSTAINED IMPROVEMENT OF LIPID PATTERN AS A RESULT OF LONG-TERM TESTOSTERONE THERAPY (TTH) OVER 13 YEARS IN MEN WITH FUNCTIONAL HYPOGONADISM (2022)
Farid Saad1,2, Ahmad Haider, Karim Haider, Gheorghe Doros, Abdulmaged Traish Consultant, Bayer AG, Berlin, Germany; Research Department, Guld Medical University, Ajman, UAE Private Urology Practice, Bremerhaven, Germany; Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA; Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction: Studies reported inconsistent effects of TTh on the lipid profile in men with hypogonadism.
Methods: In a registry of 797 men with symptomatic functional hypogonadism, 394 men (49.5%) received TTh by testosterone undecanoate (TU) injections 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported.
Results: Mean age at baseline: 58.5±6.3 (T-group), 63.2±4.8 (CTRL). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years.
*Total cholesterol (TC) (mmol/L for all lipids) decreased from 8.0±1.1 to 5.1±0.3 (T-group) and increased from 6.6±1.3 to 8.0±1.3 (CTRL) (p<0.0001 for both).
*HDL increased from 1.0±0.3 to 1.6±0.3 (T-group) and decreased from 1.2±0.5 to 0.9±0.4 (CTRL) (p<0.0001 for both).
*The TC: HDL ratio decreased from 9.1±3.6 to 3.3±0.6 (T-group) and increased from 6.5±3.4 to 11.4±5.6 (CTRL) (p<0.0001 for both).
*LDL decreased from 4.4±0.9 to 2.5±0.3 (T-group) and increased from 3.5±1.3 to 4.6±1.5 (CTRL) (p<0.0001 for both).
*Triglycerides (TG) decreased from 3.2±0.6 to 2.2±0.1 (T-group) and increased from 3.0±0.5 to 3.7±0.6 (CTRL) (p<0.0001 for both).
*The LDL: HDL ratio decreased from 5.1±2.5 to 1.7±0.4 (T-group) and increased from 3.6±2.6 to 6.8±4.5 (CTRL) (p<0.0001 for both).
*The HDL:LDL ratio increased from 0.24±0.10 to 0.64±0.13 (T-group) and decreased from 0.41±0.22 to 0.22±0.13 (CTRL) (p<0.0001 for both).
*Non-HDL decreased from 7.0±1.0 to 3.5±0.3 (T-group) and increased from 5.4±1.4 to 7.2±1.4 (CTRL) (p<0.0001 for both).
*Remnant cholesterol decreased from 2.6±0.9 to 1.0±0.3 (T-group) and increased from 1.9±0.9 to 2.6±0.8 (CTRL) (p<0.0001 for both).
*The TG: HDL ratio decreased from 8.4±3.7 to 3.2±0.6 (T-group) and increased from 6.7±3.5 to 11.7±5.7 (CTRL) (p<0.0001 for both).
Conclusion: Long-term treatment with TU in men with functional hypogonadism improved the lipid profile, which worsened in controls.
Farid Saad1,2, Ahmad Haider, Karim Haider, Gheorghe Doros, Abdulmaged Traish Consultant, Bayer AG, Berlin, Germany; Research Department, Guld Medical University, Ajman, UAE Private Urology Practice, Bremerhaven, Germany; Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA; Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction: Studies reported inconsistent effects of TTh on the lipid profile in men with hypogonadism.
Methods: In a registry of 797 men with symptomatic functional hypogonadism, 394 men (49.5%) received TTh by testosterone undecanoate (TU) injections 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported.
Results: Mean age at baseline: 58.5±6.3 (T-group), 63.2±4.8 (CTRL). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years.
*Total cholesterol (TC) (mmol/L for all lipids) decreased from 8.0±1.1 to 5.1±0.3 (T-group) and increased from 6.6±1.3 to 8.0±1.3 (CTRL) (p<0.0001 for both).
*HDL increased from 1.0±0.3 to 1.6±0.3 (T-group) and decreased from 1.2±0.5 to 0.9±0.4 (CTRL) (p<0.0001 for both).
*The TC: HDL ratio decreased from 9.1±3.6 to 3.3±0.6 (T-group) and increased from 6.5±3.4 to 11.4±5.6 (CTRL) (p<0.0001 for both).
*LDL decreased from 4.4±0.9 to 2.5±0.3 (T-group) and increased from 3.5±1.3 to 4.6±1.5 (CTRL) (p<0.0001 for both).
*Triglycerides (TG) decreased from 3.2±0.6 to 2.2±0.1 (T-group) and increased from 3.0±0.5 to 3.7±0.6 (CTRL) (p<0.0001 for both).
*The LDL: HDL ratio decreased from 5.1±2.5 to 1.7±0.4 (T-group) and increased from 3.6±2.6 to 6.8±4.5 (CTRL) (p<0.0001 for both).
*The HDL:LDL ratio increased from 0.24±0.10 to 0.64±0.13 (T-group) and decreased from 0.41±0.22 to 0.22±0.13 (CTRL) (p<0.0001 for both).
*Non-HDL decreased from 7.0±1.0 to 3.5±0.3 (T-group) and increased from 5.4±1.4 to 7.2±1.4 (CTRL) (p<0.0001 for both).
*Remnant cholesterol decreased from 2.6±0.9 to 1.0±0.3 (T-group) and increased from 1.9±0.9 to 2.6±0.8 (CTRL) (p<0.0001 for both).
*The TG: HDL ratio decreased from 8.4±3.7 to 3.2±0.6 (T-group) and increased from 6.7±3.5 to 11.7±5.7 (CTRL) (p<0.0001 for both).
Conclusion: Long-term treatment with TU in men with functional hypogonadism improved the lipid profile, which worsened in controls.
